RBBP6

Across TCGA pan-cancer cohorts, RBBP6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBBP6 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RBBP6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RBBP6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where RBBP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.734	0.345	.001	33	view →
CCRCC	OS	Quartile	III,IV	0.453	0.923	.011	19	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	12	view →
HNSC	OS	Median	II,III,IV	1.000	0.955	.027	3	view →
GBM	DFS	Quartile	All	0.502	0.203	.031	2	view →
LSCC	OS	Tertile	All	1.000	0.959	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBBP6–LUAD (DFS)

Open the LUAD breakdown →